Anti-Human CD112/Nectin-2/PVRL2 Antibody (SAA2364)
Your go-to solution for advanced biotech research.
This highly specific antibody targets the CD112/Nectin-2/PVRL2 protein, a cell adhesion molecule that plays a crucial role in immune response and cell-to-cell interactions. By binding to this protein, our Anti-Human CD112/Nectin-2/PVRL2 Antibody (SAA2364) effectively blocks its function, making it an essential tool for studying its biological function.
Our antibody has been extensively tested and validated for use in a variety of applications, including flow cytometry, immunohistochemistry, and western blotting. Its high specificity and sensitivity make it a reliable choice for detecting and quantifying CD112/Nectin-2/PVRL2 expression in various cell types and tissues.
But that’s not all – the Anti-Human CD112/Nectin-2/PVRL2 Antibody (SAA2364) has also been proven to be effective in inhibiting the growth and proliferation of certain cancer cells. This makes it a promising candidate for potential cancer therapies and further research in this field.
In addition, our antibody has been successfully used in experimental settings to investigate the role of CD112/Nectin-2/PVRL2 in autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Its ability to specifically target this protein allows for more accurate and reliable results in these studies.
At [Company Name], we understand the importance of precise and reliable research tools in the biotech industry. That’s why we have developed the Anti-Human CD112/Nectin-2/PVRL2 Antibody (SAA2364) – a highly specific and sensitive antibody that will elevate your research to the next level.
So if you’re looking for a top-notch antibody for your biotech research, choose the Anti-Human CD112/Nectin-2/PVRL2 Antibody (SAA2364). With its proven efficacy and versatility, it is the perfect choice for studying the biological function of CD112/Nectin-2/PVRL2 and its potential applications in various diseases. Order now and take your research to new heights.
There are no reviews yet.